Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Lisa von Moltke"'
Autor:
Colleen S. Kraft, Matthew Sims, Michael Silverman, Thomas J. Louie, Paul Feuerstadt, Edward S. Huang, Sahil Khanna, Charles S. Berenson, Elaine E. L. Wang, Stuart H. Cohen, Louis Korman, Christine Lee, Colleen R. Kelly, Alberto Odio, Paul P. Cook, Bret Lashner, Mayur Ramesh, Princy Kumar, Ananya De, Asli Memisoglu, David A. Lombardi, Brooke R. Hasson, Barbara H. McGovern, Lisa von Moltke, Darrell S. Pardi, on behalf of the ECOSPOR III and ECOSPOR IV investigators
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 10, Pp 2105-2121 (2024)
Abstract Introduction Recurrent Clostridioides difficile infection (rCDI) often occurs after standard-of-care antibiotics. VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to preven
Externí odkaz:
https://doaj.org/article/ba87c7a699914c4c8d06cf93ba025fb8
Autor:
Colleen S. Kraft, Matthew Sims, Michael Silverman, Thomas J. Louie, Paul Feuerstadt, Edward S. Huang, Sahil Khanna, Charles S. Berenson, Elaine E. L. Wang, Stuart H. Cohen, Louis Korman, Christine Lee, Colleen R. Kelly, Alberto Odio, Paul P. Cook, Bret Lashner, Mayur Ramesh, Princy Kumar, Ananya De, Asli Memisoglu, David A. Lombardi, Brooke R. Hasson, Barbara H. McGovern, Lisa von Moltke, Darrell S. Pardi, on behalf of the ECOSPOR III and ECOSPOR IV investigators
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 10, Pp 2209-2210 (2024)
Externí odkaz:
https://doaj.org/article/f16a0014b1ca4cc2a94f3e0768a3e630
Autor:
Matthew Sims, Charles Berenson, Stuart Cohen, Elaine Wang, Elizabeth Hohmann, Richard Nathan, Alberto Odio, Paul Cook, Kelly Brady, David Lombardi, Asli Memisoglu, Ananya De, Brooke Hasson, Bret Lashner, Louis Korman, Doria Grimard, Juan Carlos Moises Gutierrez, Barbara McGovern, Lisa Von Moltke
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 3, Pp s44-s45 (2023)
Background: Clostridioides difficile infection (CDI) often recurs in patients aged ≥65 years and those with comorbidities. Clinical trials often exclude patients with history of immunosuppression, malignancy, renal insufficiency, or other comorbidi
Externí odkaz:
https://doaj.org/article/880265aec59442dcb47cf58a1e5edb98
Autor:
Matthew Sims, Michael Silverman, Thomas Louie, Elaine Wang, Colleen Kraft, Mayur Ramesh, Tatiana Bogdanovich, Kelly Brady, David Lombardi, Asli Memisoglu, Ananya De, Brooke Hasson, Christine Lee, Paul Feuerstadt, Darrell Pardi, Colleen Kelly, Peter Daley, Godson Oguchi, Barbara McGovern, Lisa Von Moltke
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 3, Pp s5-s5 (2023)
Background: Antibiotics alone are often insufficient to treat recurrent C. difficile infection (rCDI) because they have no activity against C. difficile spores that germinate within a disrupted microbiome. SER-109, an investigational, oral, microbiom
Externí odkaz:
https://doaj.org/article/d78d9777975443acb4dd1a9279e57b73
Autor:
Stuart Cohen, Thomas Louie, Charles Berenson, Alpesh Amin, David Lombardi, Sissi Pham, Shirley Huang, Elaine Wang, Brooke Hasson, Barbara McGovern, Lisa Von Moltke
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 2, Pp s73-s73 (2022)
Background: The estimated economic cost of Clostridioides difficile infection (CDI) is $5.4 billion annually, primarily attributed to acute-care costs. We previously reported data from ECOSPOR III that SER-109, an investigational oral microbiome ther
Externí odkaz:
https://doaj.org/article/4aa43028951049daabfd2cad4d796d9e
Autor:
Sahil Khanna, Matthew Sims, Thomas J. Louie, Monika Fischer, Kerry LaPlante, Jessica Allegretti, Brooke R. Hasson, Allyson T. Fonte, Christopher McChalicher, David S. Ege, Jessica A. Bryant, Timothy J. Straub, Christopher B. Ford, Matthew R. Henn, Elaine E. L. Wang, Lisa von Moltke, Mark H. Wilcox
Publikováno v:
Antibiotics, Vol 11, Iss 9, p 1234 (2022)
Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20–25% of patients with a primary infection expe
Externí odkaz:
https://doaj.org/article/d75c22c7d85f46b889c85299de3a01eb
Publikováno v:
Drugs in R&D, Vol 19, Iss 3, Pp 277-287 (2019)
Abstract Background and Objectives Samidorphan (SAM) is a novel μ-opioid receptor antagonist. We report clinical pharmacokinetic (PK) properties of SAM following different routes of administration, and the effects of food and age on the PK of SAM fo
Externí odkaz:
https://doaj.org/article/5dbc12a4dc9c44f38dc7b1e9e279a1ee
Autor:
Marjie L. Hard, Angela Wehr, Lisa von Moltke, Yangchun Du, Sarah Farwick, David P. Walling, John Sonnenberg
Publikováno v:
Therapeutic Advances in Psychopharmacology, Vol 9 (2019)
Background: Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia in adults, can be started with either 21 days of daily oral aripiprazole supplementation or a 1-day initiation regimen consisting of a s
Externí odkaz:
https://doaj.org/article/500584bb4a2a4749bda3c08007f9433d
Autor:
Paul Feuerstadt, Thomas J. Louie, Bret Lashner, Elaine E.L. Wang, Liyang Diao, Jessica A. Bryant, Matthew Sims, Colleen S. Kraft, Stuart H. Cohen, Charles S. Berenson, Louis Y. Korman, Christopher B. Ford, Kevin D. Litcofsky, Mary-Jane Lombardo, Jennifer R. Wortman, Henry Wu, John G. Auniņš, Christopher W.J. McChalicher, Jonathan A. Winkler, Barbara H. McGovern, Michele Trucksis, Matthew R. Henn, Lisa von Moltke
Publikováno v:
New England Journal of Medicine. 386:220-229
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d55eeabd157c79df7bb5ebb71cc44fe
https://doi.org/10.1056/nejmoa2106516
https://doi.org/10.1056/nejmoa2106516
Autor:
Brian Feagan, David Rubin, Stephen Hanauer, William Sandborn, Walter Reinisch, David Lichter, Barbara McGovern, Judith Bebchuk, Guangyong Zou, Sherry Wang-Weigand, Mark Sostek, Lisa von Moltke
Publikováno v:
Gastroenterology. 164:S23-S24
BACKGROUND Endoscopic assessment of disease severity is a key component of ulcerative colitis (UC) clinical studies. However, interobserver variability may contribute to bias in selecting study candidates and evaluating response rates. Scoring by bli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d5b1efc77a00127ce1dfac40e3ee32e
https://doi.org/10.1053/j.gastro.2023.03.053
https://doi.org/10.1053/j.gastro.2023.03.053